Pages that link to "Q71688012"
Jump to navigation
Jump to search
The following pages link to Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity (Q71688012):
Displaying 44 items.
- Kallikreins as biomarkers for prostate cancer (Q26862434) (← links)
- Male hypogonadism (Q28300144) (← links)
- Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy (Q33534840) (← links)
- Prostate cancer: A challenge for screening. (Q33714893) (← links)
- Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians (Q33744340) (← links)
- Cancer screening in the elderly population (Q33841144) (← links)
- The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program (Q34076905) (← links)
- Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy (Q34230601) (← links)
- Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). (Q34555011) (← links)
- The role of prostate-specific antigen velocity in prostate cancer early detection (Q34707807) (← links)
- Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan (Q35117241) (← links)
- Early diagnosis and surgical management of prostate cancer (Q35145693) (← links)
- Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy (Q35591116) (← links)
- A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly (Q36410718) (← links)
- Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study (Q36512827) (← links)
- Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer? (Q36575790) (← links)
- Tumor markers in prostate cancer I: blood-based markers (Q36607766) (← links)
- New circulating biomarkers for prostate cancer (Q36999680) (← links)
- The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. (Q37016899) (← links)
- Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics (Q37037804) (← links)
- Screening for prostate cancer: an update. (Q37338478) (← links)
- Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. (Q37469461) (← links)
- Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study (Q37496282) (← links)
- Risk-based prostate cancer screening. (Q37963657) (← links)
- Risk-based prostate cancer screening: who and how? (Q38093463) (← links)
- PSA velocity: a systematic review of clinical applications (Q38224140) (← links)
- Prevalence and Predictors of a Positive Repeat Transrectal Ultrasound Guided Needle Biopsy of the Prostate (Q39449332) (← links)
- The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction (Q39454488) (← links)
- Effect of transurethral resection on serum free/total prostate-specific antigen levels in patients with benign prostatic hyperplasia (Q39484072) (← links)
- Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? (Q39638396) (← links)
- Is screening for prostate cancer the current gold standard?--"no". (Q41474108) (← links)
- Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years. (Q42141399) (← links)
- Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam (Q43631091) (← links)
- Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study (Q43863865) (← links)
- Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer (Q46247259) (← links)
- Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. (Q46779029) (← links)
- Prostate-specific antigen velocity in healthy Korean men with initial PSA levels of 4.0 ng/mL or less. (Q46847182) (← links)
- Prostate-specific antigen velocity and repeated measures of prostate-specific antigen (Q73286315) (← links)
- Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer (Q73328627) (← links)
- Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial (Q73807682) (← links)
- [Role of PSA velocity in the detection of prostate cancer. A study of 986 males] (Q74010719) (← links)
- PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml (Q74179436) (← links)
- Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? (Q81909492) (← links)
- PSA velocity and PSA slope (Q82987640) (← links)